SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        Date of Report: September 2, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                               Delaware 52-1555759
                    (State of Incorporation) (I.R.S. Employer
                               Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


Registrant's telephone number, including area code (301) 417-0770


No Exhibits are being filed with this report


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.






MEDIMMUNE, INC.
Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated September 1, 1999:

              ABBOTT ANNOUNCES APPROVAL OF BREAKTHROUGH PREVENTION
                                FOR RSV IN EUROPE
                       - Synagis Now Available In Europe -

Abbott Park, IL and Gaithersburg,  MD, September 1, 1999 -- Abbott  Laboratories
(NYSE:ABT)  and  MedImmune,  Inc.  (Nasdaq:MEDI)  today  announced  the European
Commission granted a marketing  authorization for Synagis  (palivizumab) for the
prevention of serious lower respiratory tract disease requiring  hospitalization
caused by respiratory  syncytial  virus (RSV) in high-risk  infants.  Synagis is
indicated  for use in infants born  prematurely  (less than or equal to 35 weeks
gestational  age),  and  infants  and  children  with  chronic  bronchopulmonary
dysplasia (BPD), a chronic lung disease.

Synagis,  the first monoclonal  antibody to be licensed in the United States for
any infectious  disease, is also the first product to deliver safe and effective
RSV protection with a simple intramuscular (IM) injection.  The injection can be
administered in the primary  health-care  provider's  office once a month during
the RSV season -- typically November to April in Europe.

RSV is the most  common  cause of lower  respiratory  infections  in infants and
children  worldwide.  In fact, half of all children around the world develop RSV
infections by the age of one year, and by the age of two, virtually all children
have been  infected.  In high-risk  children  infected  with RSV, 70 percent may
require hospitalization,  25 percent may require mechanical ventilation and some
may die as a result of RSV infection.

"RSV can be a  life-threatening  disease for premature babies and young children
with BPD," says David Goffredo,  Vice President,  European  Operations,  Abbott.
"Synagis has the potential to enhance patient care, reduce costs associated with
prolonged  hospital stays and reassure parents that they are taking an important
step to help improve their child's health and well-being."

The U.S. Food and Drug  Administration  (FDA) approved  Synagis for marketing in
June 1998.

RSV Studies
A  placebo-controlled,  randomized  study  -- one of the  largest  studies  ever
conducted   in  premature   infants-   showed   Synagis   reduced  the  risk  of
hospitalization  due to RSV by 55 percent.  Studies were  conducted in premature
infants,  including  those  with  BPD.  The  most  frequently  reported  adverse
reactions were fever,  nervousness  and injection  site reaction,  however these
rates were similar in the treatment versus placebo groups.

In addition to its success in preventing  RSV,  Synagis does not interfere  with
normal childhood  vaccines including the  measles-mumps-rubella  vaccine and the
varicella virus vaccine.

About RSV
Common  symptoms  of RSV include a low-grade  fever,  runny nose and cough.  The
cough may be  accompanied  by wheezing and  difficulty in  breathing,  which can
indicate that the virus has moved to the lower  respiratory  tract.  RSV spreads
easily from person to person via  sneezing or coughing,  or from hands  touching
the nose or eyes and then coming in contact with another  person or object.  The
chance  of  spreading  the  virus  within a family  is very  high;  many  times,
school-aged  children  introduce  the  virus  into the  family.  Despite  strict
infection  control  procedures,  hospital nursery units,  day care centers,  and
other similar institutions are also at high-risk for RSV outbreaks.

"Synagis  represents  a major  breakthrough  in RSV  prevention,"  said  William
Dempsey, Senior Vice President,  International Operations,  Abbott Laboratories.
"Abbott  believes  Synagis will  provide  high-risk  children  with even greater
protection against this disease."

"We are pleased  with the  European  Commission's  decision to approve  Synagis
 for  marketing  in Europe,"  commented  Melvin D. Booth, President and Chief
Operating Officer at MedImmune.  "RSV is a worldwide  problem,  and we, with
our colleagues at Abbott,  want to make Synagis globally available."


In December 1997,  Abbott  Laboratories and MedImmune,  Inc. formed an exclusive
worldwide marketing alliance to commercialize Synagis.  Abbott has the exclusive
right to market and distribute  Synagis outside the United States.  In the U.S.,
where Synagis was approved for marketing in June 1998, MedImmune and Abbott have
an agreement to co-promote the product.

Abbott Laboratories is a global,  diversified health care company devoted to the
discovery,   development,   manufacturing   and  marketing  of   pharmaceutical,
diagnostic, nutritional and hospital products. Abbott Laboratories is located in
Abbott Park,  Ill. The company employs 56,000 people and markets its products in
more than 130 countries.

MedImmune,  Inc.,  located in  Gaithersburg,  Md.,  is a  biotechnology  company
focused on developing and marketing products that address medical needs in areas
such as infectious disease,  transplantation medicine,  autoimmune disorders and
cancer.  MedImmune markets three products through its hospital-based sales force
and has five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number  of  factors,  including  risks  and  uncertainties  discussed  in both
companies' filings with the U.S. Securities and Exchange Commission.



                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                    MEDIMMUNE,INC.
                                    --------------
                                    (Registrant)


September 2, 1999                   /s/ David M. Mott
                                    -----------------
                                    David M. Mott, Vice Chairman and
                                    Chief Financial Officer